• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Research Brief on 3-(1-Ethylcyclopropyl)-1-methyl-1H-pyrazol-5-amine (CAS: 1865008-26-9): Recent Advances and Applications

The compound 3-(1-Ethylcyclopropyl)-1-methyl-1H-pyrazol-5-amine (CAS: 1865008-26-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, mechanism of action, and emerging roles in drug discovery.

Recent studies have highlighted the compound's role as a key intermediate in the synthesis of novel kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of selective JAK2 inhibitors, which show promise for treating myeloproliferative neoplasms. The ethylcyclopropyl moiety in the structure appears to confer enhanced metabolic stability compared to earlier analogs, addressing a critical challenge in kinase inhibitor design.

In terms of synthetic methodology, a breakthrough was reported in Organic Letters (2024) describing a novel one-pot cyclization approach to produce 3-(1-Ethylcyclopropyl)-1-methyl-1H-pyrazol-5-amine with 78% yield and excellent enantioselectivity. This represents a significant improvement over previous multi-step synthetic routes and may facilitate larger-scale production for preclinical studies.

Pharmacological characterization studies have revealed interesting properties of this compound. Research from the University of Cambridge (2024) indicates that it exhibits moderate blood-brain barrier penetration, suggesting potential applications in CNS-targeted therapies. Additionally, its metabolic profile shows favorable hepatic stability across multiple species, as reported in recent ADME studies.

The compound has also emerged as a valuable tool in chemical biology. A Nature Chemical Biology publication (2023) detailed its use as a versatile scaffold for developing activity-based protein profiling probes, particularly for studying pyrazole-sensitive enzymes. This application leverages the compound's inherent selectivity and modifiable amine functionality.

Several pharmaceutical companies have included derivatives of 3-(1-Ethylcyclopropyl)-1-methyl-1H-pyrazol-5-amine in their pipelines. Current patent filings (2023-2024) suggest applications ranging from inflammatory diseases to oncology, with particular emphasis on its combination with immune checkpoint inhibitors. The compound's ability to modulate specific cytokine signaling pathways appears to be a key factor in these therapeutic strategies.

Looking forward, researchers anticipate that further exploration of this scaffold may yield novel therapeutics with improved selectivity and safety profiles. Ongoing structure-activity relationship studies aim to optimize the balance between potency and pharmacokinetic properties. The compound's versatility and demonstrated biological activity position it as an important focus area in medicinal chemistry research for the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)